Logo

American Heart Association

  2
  0


Final ID: Mo2198

The Distinct Natural History, Phenotype Spectrum, Familial Penetrance and Clinical Outcomes in Desmin (DES)-Associated Cardiomyopathy

Abstract Body (Do not enter title and authors here): Background: Pathogenic/likely pathogenic variants (P/LP) in the desmin (DES) gene cause heterogeneous cardiomyopathy and skeletal myopathy phenotypes.
Research Questions: Limited data suggest that patients with P/LP DES variants have a high incidence of major adverse cardiac events (MACEs), including cardiac conduction disease requiring pacemaker implantation (CCD-PM), sustained ventricular arrhythmias (VA), and heart failure (HF) events (HF hospitalization, heart transplant, HF-related death). However, small cohort sizes have limited full clinical characterization.
Aims: We aimed to describe the natural history, phenotype spectrum, familial penetrance and MACE in patients with P/LP DES variants identified via clinical genetic testing.
Methods: We conducted a systematic review and individual patient data meta-analysis of cardiac and skeletal myopathy phenotypes and MACE (CCD-PM, VA and HF events) in patients with P/LP DES variants by retrieving publications from Medline (PubMed) and Embase. Diagnosis of cardiomyopathy or MACE were both considered evidence of cardiac involvement.
Results: Out of 4,212 screened records, 72 met inclusion criteria. In total, 230 patients were included (52.6% male, 52.2% probands, median age: 31 years at first evaluation [22.0; 42.8]). Eighty-five (37.0%) patients showed isolated cardiac involvement, 89 (38.7%) cardiac and skeletal muscle involvement, 39 (17.0%) only skeletal muscle involvement, and 17 (7.4%) had neither phenotype. Overall, 130 (56.5%) patients were diagnosed with a cardiomyopathy and 134 (57.4%) patients developed MACE (96 [41.7%] had CCD-PM, 36 [15.7%] sustained VA, and 43 [18.7%] HF events). Familial cardiac disease penetrance was 69.1% (76/110) in relatives with P/LP DES variants. Out of 40 patients who presented with isolated CCD-PM phenotype, 18 (45.0%) were diagnosed with a cardiomyopathy after 6 [2.0; 16.0] years of follow-up. In multivariable analysis, male sex and non-missense variants were associated with higher risk of sustained VA (HR 2.71, p=0.008, and HR 4.62, p<0.001, respectively) and HF events (HR 2.63, p=0.005, and HR 2.79, p=0.015).
Conclusions: DES cardiomyopathy demonstrates a distinct natural history, characterized by high familial penetrance and a high MACE burden. Male patients and those carrying non-missense variants are at higher risk for sustained VA events and may benefit from primary preventive ICD implantation even in the absence of severe LV systolic dysfunction.
  • Asatryan, Babken  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Zimmerman, Stefan  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Calkins, Hugh  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • James, Cynthia  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Barth, Andreas  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Rieder, Marina  ( Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland )
  • Muller, Steven  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Murray, Brittney  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Tichnell, Crystal  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Gasperetti, Alessio  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Carrick, Richard  ( Johns Hopkins University School of Medicine , Baltimore , Maryland , United States )
  • Te Riele, Anneline  ( UNIVERSITY MEDICAL CENTER UTRECHT , Utrecht , Netherlands )
  • Joseph, Emily  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Author Disclosures:
    Babken Asatryan: DO NOT have relevant financial relationships | Stefan Zimmerman: DO NOT have relevant financial relationships | Hugh Calkins: DO have relevant financial relationships ; Consultant:Atricure:Active (exists now) ; Consultant:Johnson and Johnson:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Cynthia James: DO have relevant financial relationships ; Research Funding (PI or named investigator):Lexeo Therapeutics:Active (exists now) ; Consultant:Lexeo Therapeutics:Past (completed) ; Consultant:Pfizer Inc:Past (completed) ; Research Funding (PI or named investigator):Tenaya Inc:Active (exists now) ; Research Funding (PI or named investigator):EicoSIS:Past (completed) ; Research Funding (PI or named investigator):StrideBio Inc:Past (completed) ; Research Funding (PI or named investigator):Arvada inc:Active (exists now) | Andreas Barth: No Answer | Marina Rieder: DO NOT have relevant financial relationships | Steven Muller: DO NOT have relevant financial relationships | Brittney Murray: DO NOT have relevant financial relationships | Crystal Tichnell: No Answer | Alessio Gasperetti: DO NOT have relevant financial relationships | Richard Carrick: DO NOT have relevant financial relationships | Anneline Te Riele: DO NOT have relevant financial relationships | Emily Joseph: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Cardiomyopathy Potpourri 2

Monday, 11/18/2024 , 01:30PM - 02:30PM

Abstract Poster Session

More abstracts on this topic:
More abstracts from these authors:
Panelist

Asatryan Babken

Incorporating Variant Databases into Patient Care

De Backer Julie, Ingles Jodie, James Cynthia

You have to be authorized to contact abstract author. Please, Login
Not Available